(Q24203878)

5

0 references

Markus Schaaf

1

object named as

Markus Schaaf

0 references

Marcel Reiser

2

object named as

Marcel Reiser

0 references

Peter Borchmann

Cochrane Database of Systematic Reviews

3

object named as

Peter Borchmann

0 references

publication date

18 January 2012

0 references

published in

0 references

cites work

High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle c

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

Frontline therapy with early intensification and autologous stem cell transplantation versus conventional chemotherapy in unselected high-risk, aggressive non-Hodgkin's lymphoma patients: a prospective randomized GEMOH report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

Late non-neoplastic events in patients with aggressive non-Hodgkin's lymphoma in four randomized European Organisation for Research and Treatment of Cancer trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: long-term results by the NHLCSG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

Interferon-alpha for follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

A systematic overview of chemotherapy effects in indolent non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

Transplantation strategies for patients with follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

Changing incidence of non-Hodgkin lymphomas in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

The epidemiology of non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

Role of hematopoietic stem cell transplant in the management of follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

The World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

Current treatment strategies in follicular lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

The case of the misleading funnel plot

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

Current treatment of follicular non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

Practical methods for incorporating summary time-to-event data into meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

Investigational strategies in autologous stem cell transplantation for follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

Frequency ofBCL2andBCL6translocations in follicular lymphoma: Relation with histological and clinical features

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

7 January 2021

[Therapy of follicular lymphoma]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

7 January 2021

Induction of anti-tumor activity following autologous stem cell transplantation: immunotherapeutic implications

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

7 January 2021

Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

7 January 2021

High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

7 January 2021

ASCT in follicular lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

7 January 2021

Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

7 January 2021

Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

7 January 2021

The natural history of initially untreated low-grade non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

7 January 2021

High-Dose Chemotherapy and Autologous Bone Marrow Transplantation Compared with MACOP-B in Aggressive B-Cell Lymphoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

7 January 2021

The CUP trial: A randomized study analyzing the efficacy of high dose therapy and purging in low-grade non-Hodgkin's lymphoma (NHL)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

7 January 2021

PARMA international protocol: pilot study on 50 patients and preliminary analysis of the ongoing randomized study (62 patients)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

7 January 2021

Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for follicular lymphoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

7 January 2021

Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas--results of a randomized comparison by the German Low-Grade Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

7 January 2021

Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lympho

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

7 January 2021

Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

7 January 2021

Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall s

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

7 January 2021

High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

7 January 2021

Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

7 January 2021

Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

7 January 2021

Follicular lymphoma: prognostic factors for response and survival

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

7 January 2021

High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multice

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

7 January 2021

VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

7 January 2021

High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Bl

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

7 January 2021

Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Stu

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

7 January 2021

Meta-analysis to evaluate the role of interferon in follicular lymphoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

7 January 2021

CHOP versus CHOP plus ESHAP and high-dose therapy with autologous peripheral blood progenitor cell transplantation for high-intermediate-risk and high-risk aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007678.PUB2

7 January 2021

10.1002/14651858.CD007678.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

22258971

1 reference

Consolidated OpenCitations Corpus – April 2017